Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

Ines Garcia-Lunar, Isabel Blanco, Leticia Fernández-Friera, Susanna Prat-Gonzàlez, Paloma Jordà, Javier Sánchez, Daniel Pereda, Sandra Pujadas, Mercedes Rivas, Eduard Solé-Gonzalez, Jorge Vázquez, Zorba Blázquez, Juan García-Picart, Pedro Caravaca, Noemí Escalera, Pablo Garcia-Pavia, Juan Delgado, Javier Segovia-Cubero, Valentín Fuster, Eulalia Roig, Joan Albert Barberá, Borja Ibanez, Ana García-Álvarez, Ines Garcia-Lunar, Isabel Blanco, Leticia Fernández-Friera, Susanna Prat-Gonzàlez, Paloma Jordà, Javier Sánchez, Daniel Pereda, Sandra Pujadas, Mercedes Rivas, Eduard Solé-Gonzalez, Jorge Vázquez, Zorba Blázquez, Juan García-Picart, Pedro Caravaca, Noemí Escalera, Pablo Garcia-Pavia, Juan Delgado, Javier Segovia-Cubero, Valentín Fuster, Eulalia Roig, Joan Albert Barberá, Borja Ibanez, Ana García-Álvarez

Abstract

Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539).

Keywords: CCT, cardiac computed tomography; CMR, cardiac magnetic resonance; CpcPH, combined pre- and post-capillary pulmonary hypertension; ECG, electrocardiography; HF, heart failure; ITT, intention to treat; IpcPH, isolated post-capillary pulmonary hypertension; LHD, left heart disease; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PP, Per protocol; PVR, pulmonary vascular resistance; RV, right ventricle; adrenoreceptors; cGMP, cyclic guanosine monophosphate; imaging; pulmonary hypertension; treatment; β3AR, beta-3 adrenoreceptor.

© 2020 The Authors.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Summary of the Study Conduct
Figure 2
Figure 2
Multimodality Imaging Evaluation of RV Performance in SPHERE-HF Trial (A) Right ventricular (RV) speckle tracking−derived strain from an apical 4-chamber view on echocardiography. (B and C) End-diastolic and end-systolic frames from the cine sequence at the mid-ventricular level to calculate biventricular volumes and ejection fraction with cardiac magnetic resonance (CMR). (D and E) T1 maps before (D) and 15 min after contrast administration (E) for estimation of extracellular volume using CMR. (F and G) Cardiac computed tomographic images from end-diastolic and end-systolic frames to calculate biventricular volumes and ejection fraction in a patient who could not undergo CMR due to an implantable cardiac resynchronization therapy device. SPHERE-HF = β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure.

References

    1. Ghio S., Gavazzi A., Campana C. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183–188.
    1. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., Redfield M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–1126.
    1. Guazzi M., Borlaug B.A. Pulmonary hypertension due to left heart disease. Circulation. 2012;126:975–990.
    1. Bursi F., McNallan S.M., Redfield M.M. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012;59:222–231.
    1. Grigioni F., Potena L., Galie N. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006;25:1241–1246.
    1. Gerges M., Gerges C., Pistritto A.M. Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med. 2015;192:1234–1246.
    1. Tatebe S., Fukumoto Y., Sugimura K. Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. Circ J. 2012;76:1235–1244.
    1. Galie N., Humbert M., Vachiery J.L. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2016;37:67–119.
    1. Vachiery J.L., Adir Y., Barbera J.A. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62:D100−8.
    1. Califf R.M., Adams K.F., McKenna W.J. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) Am Heart J. 1997;134:44–54.
    1. Kalra P.R., Moon J.C., Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195–197.
    1. Vachiery J.L., Delcroix M., Al-Hiti H. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51
    1. Lewis G.D., Shah R., Shahzad K. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555–1562.
    1. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–174.
    1. Redfield M.M., Chen H.H., Borlaug B.A. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–1277.
    1. Hoendermis E.S., Liu L.C., Hummel Y.M. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36:2565–2573.
    1. Bermejo J., Yotti R., Garcia-Orta R. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39:1255–1264.
    1. Bonderman D., Pretsch I., Steringer-Mascherbauer R. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146:1274–1285.
    1. Bonderman D., Ghio S., Felix S.B. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502–511.
    1. Moniotte S., Kobzik L., Feron O., Trochu J.N., Gauthier C., Balligand J.L. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001;103:1649–1655.
    1. Dessy C., Moniotte S., Ghisdal P., Havaux X., Noirhomme P., Balligand J.L. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004;110:948–954.
    1. Rozec B., Gauthier C. Beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther. 2006;111:652–673.
    1. Baliga R.S., MacAllister R.J., Hobbs A.J. New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol. 2011;163:125–140.
    1. Aragon J.P., Condit M.E., Bhushan S. Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol. 2011;58:2683–2691.
    1. Garcia-Prieto J., Garcia-Ruiz J.M., Sanz-Rosa D. β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes. Basic Res Cardiol. 2014;109:422.
    1. Niu X., Zhao L., Li X. β3-adrenoreceptor stimulation protects against myocardial infarction injury via eNOS and nNOS activation. PLoS One. 2014;9
    1. Bundgaard H., Liu C.C., Garcia A. β(3) adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation. 2010;122:2699–2708.
    1. Niu X., Watts V.L., Cingolani O.H. Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol. 2012;59:1979–1987.
    1. Belge C., Hammond J., Dubois-Deruy E. Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014;129:451–462.
    1. Garcia-Alvarez A., Pereda D., Garcia-Lunar I. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. Basic Res Cardiol. 2016;111:49.
    1. Malik M., van Gelderen E.M., Lee J.H. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92:696–706.
    1. Chapple C.R., Amarenco G., Lopez Aramburu M.A. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32:1116–1122.
    1. Chapple C.R., Dvorak V., Radziszewski P. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24:1447–1458.
    1. Chapple C.R., Kaplan S.A., Mitcheson D. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.
    1. Herschorn S., Barkin J., Castro-Diaz D. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–320.
    1. Khullar V., Amarenco G., Angulo J.C. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295.
    1. Nitti V.W., Auerbach S., Martin N., Calhoun A., Lee M., Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–1395.
    1. Bundgaard H., Axelsson A., Hartvig Thomsen J. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail. 2017;19:566–575.
    1. Gerges C., Gerges M., Lang M.B. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest. 2013;143:758–766.
    1. Holland A.E., Spruit M.A., Troosters T. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–1446.
    1. Lang R.M., Badano L.P., Mor-Avi V. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–270.
    1. Rudski L.G., Lai W.W., Afilalo J. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685–713. quiz 86−8.
    1. Zoghbi W.A., Adams D., Bonow R.O. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–371.
    1. Nagueh S.F., Smiseth O.A., Appleton C.P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321–1360.
    1. Baumgartner H., Hung J., Bermejo J. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372–392.
    1. Garcia-Alvarez A., Fernandez-Friera L., Garcia-Ruiz J.M. Noninvasive monitoring of serial changes in pulmonary vascular resistance and acute vasodilator testing using cardiac magnetic resonance. J Am Coll Cardiol. 2013;62:1621–1631.
    1. Sanz J., Garcia-Alvarez A., Fernandez-Friera L. Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study. Heart. 2012;98:238–243.
    1. Garcia-Alvarez A., Garcia-Lunar I., Pereda D. Association of myocardial T1-mapping CMR with hemodynamics and RV performance in pulmonary hypertension. J Am Coll Cardiol Img. 2015;8:76–82.
    1. Heath D., Edwards J.E. Histological changes in the lung in diseases associated with pulmonary venous hypertension. Br J Dis Chest. 1959;53:8–18.
    1. Vanderpool R.R., Naeije R. Progress in pulmonary hypertension with left heart failure. Beyond new definitions and acronyms. Am J Respir Crit Care Med. 2015;192:1152–1154.
    1. Packer M., McMurray J., Massie B.M. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11:12–20.
    1. Swiston J.R., Johnson S.R., Granton J.T. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med. 2010;104:1588–1607.
    1. Chang P.P., Longenecker J.C., Wang N.Y. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant. 2005;24:998–1007.
    1. Rosenkranz S., Gibbs J.S., Wachter R., De Marco T., Vonk-Noordegraaf A., Vachiery J.L. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37:942–954.
    1. Vonk Noordegraaf A., Westerhof B.E., Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. J Am Coll Cardiol. 2017;69:236–243.
    1. Assad T.R., Hemnes A.R., Larkin E.K. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;68:2525–2536.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅